OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
459558

Mizuho Medy Co Ltd

Medical Equipment, Supplies & DistributionVerified

Mizuho Medy maintains a strong liquidity position, with cash and equivalents amounting to ¥10.83 billion, representing nearly half of its total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 7.36 suggests robust short-term liquidity, well above the industry median for medical equipment and distribution firms. Profitability metrics for Mizuho Medy are strong, with a return on equity (ROE) of 18.34% and a return on assets (ROA) of 15.31%. These figures exceed the industry median for ROE and ROA in the medical equipment and distribution sector, indicating efficient use of equity and assets to generate returns. The company's revenue is concentrated in its core medical equipment and supplies business, with no disclosed geographic diversification in the provided data. This suggests a high degree of revenue concentration in its primary business segment, which may expose the company to sector-specific risks. Mizuho Medy's growth trajectory appears stable, with no significant revenue growth or decline reported in the latest financial data. The company's operating cash flow of ¥1.96 billion and free cash flow of ¥1.33 billion support its operational flexibility and capacity for reinvestment. Analysts have assigned a neutral recommendation, with a mean price target of ¥1,850 and a single "hold" rating. Risk factors for Mizuho Medy are currently low, with no immediate liquidity or dilution flags detected. The company has no long-term debt and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No recent filings or transcripts indicate material risk events or strategic shifts. Recent analyst estimates reflect a neutral outlook, with a mean recommendation of 3.00 (on a 1-5 scale) and a single "hold" rating. The lack of strong buy or buy ratings suggests limited upside potential in the near term, though the company's strong liquidity and profitability position it well for long-term stability.

30-day price · 4595(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMizuho Medy Co Ltd
Ticker4595.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Mizuho Medy Co Ltd provides medical equipment, supplies, and distribution services in the healthcare sector, generating revenue primarily through the sale and distribution of medical devices and related products.

Classification. Mizuho Medy is classified under the Healthcare Services & Equipment business sector and the Medical Equipment, Supplies & Distribution industry, with a classification confidence of 0.92.

Mizuho Medy maintains a strong liquidity position, with cash and equivalents amounting to ¥10.83 billion, representing nearly half of its total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 7.36 suggests robust short-term liquidity, well above the industry median for medical equipment and distribution firms. Profitability metrics for Mizuho Medy are strong, with a return on equity (ROE) of 18.34% and a return on assets (ROA) of 15.31%. These figures exceed the industry median for ROE and ROA in the medical equipment and distribution sector, indicating efficient use of equity and assets to generate returns. The company's revenue is concentrated in its core medical equipment and supplies business, with no disclosed geographic diversification in the provided data. This suggests a high degree of revenue concentration in its primary business segment, which may expose the company to sector-specific risks. Mizuho Medy's growth trajectory appears stable, with no significant revenue growth or decline reported in the latest financial data. The company's operating cash flow of ¥1.96 billion and free cash flow of ¥1.33 billion support its operational flexibility and capacity for reinvestment. Analysts have assigned a neutral recommendation, with a mean price target of ¥1,850 and a single "hold" rating. Risk factors for Mizuho Medy are currently low, with no immediate liquidity or dilution flags detected. The company has no long-term debt and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No recent filings or transcripts indicate material risk events or strategic shifts. Recent analyst estimates reflect a neutral outlook, with a mean recommendation of 3.00 (on a 1-5 scale) and a single "hold" rating. The lack of strong buy or buy ratings suggests limited upside potential in the near term, though the company's strong liquidity and profitability position it well for long-term stability.
Key takeaways
  • Mizuho Medy has a strong liquidity position with ¥10.83 billion in cash and equivalents and no long-term debt.
  • The company's ROE of 18.34% and ROA of 15.31% exceed industry medians, indicating strong profitability.
  • Revenue is concentrated in the core medical equipment and supplies business, with no geographic diversification disclosed.
  • Analysts have assigned a neutral outlook, with a mean price target of ¥1,850 and a single "hold" rating.
  • No immediate liquidity or dilution risks are present, and the company's capital structure is conservative.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$11.26B
Gross profit$7.82B
Operating income$4.64B
Net income$3.43B
R&D
SG&A
D&A
SBC
Operating cash flow$1.96B
CapEx-$283.0M
Free cash flow$1.33B
Total assets$22.38B
Total liabilities$3.69B
Total equity$18.68B
Cash & equivalents$10.82B
Long-term debt$0.00
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$18.68B
Net cash$10.82B
Current ratio7.4
Debt/Equity0.0
ROA15.3%
ROE18.3%
Cash conversion57.0%
CapEx/Revenue-2.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric4595Activity
Op margin41.2%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin30.4%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin69.4%64.0% medp25 60.1% · p75 65.6%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.5%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity0.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Mean price target1,850.00 JPY
Median price target1,850.00 JPY
High price target1,850.00 JPY
Low price target1,850.00 JPY
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate169.60 JPY
Last actual EPS179.80 JPY
Source: analysis-pipeline (hybrid)Generated: 2026-05-24 21:30 UTCJob: 21c55899